{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:46:17Z","timestamp":1793598377352,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Several chemotherapeutic agents act by increasing DNA damage in cancer cells, triggering cell death. However, there is limited understanding of the extent and long-term consequences of collateral DNA damage in normal tissues. To investigate the impact of chemotherapy on mutation burdens and the cell population structure of normal tissue, we sequenced blood cell genomes from 23 individuals aged 3\u201380 years who were treated with a range of chemotherapy regimens. Substantial additional somatic mutation loads with characteristic mutational signatures were imposed by some chemotherapeutic agents, but the effects were dependent on the drug and blood cell types. Chemotherapy induced premature changes in the cell population structure of normal blood, similar to those caused by normal aging. The results show the long-term biological consequences of cytotoxic agents to which a substantial fraction of the population is exposed as part of disease management, raising mechanistic questions and highlighting opportunities for the mitigation of adverse effects.<\/jats:p>","DOI":"10.1038\/s41588-025-02234-x","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:02:35Z","timestamp":1751346155000},"page":"1684-1694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["The long-term effects of chemotherapy on normal blood cells"],"prefix":"10.1038","volume":"57","author":[{"given":"Emily","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-0733","authenticated-orcid":false,"given":"My H.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Clay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-9216","authenticated-orcid":false,"given":"Rashesh","family":"Sanghvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3989-9167","authenticated-orcid":false,"given":"Nicholas","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne I.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Friesgaard","family":"\u00d8bro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunchul","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6761-6510","authenticated-orcid":false,"given":"Aditi","family":"Vedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4904-1041","authenticated-orcid":false,"given":"Sarah","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-2369","authenticated-orcid":false,"given":"Jingwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3486-3168","authenticated-orcid":false,"given":"Daniel","family":"Leonganmornlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5320-8193","authenticated-orcid":false,"given":"Michael","family":"Spencer Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Dunstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4449-2196","authenticated-orcid":false,"given":"Anna","family":"Santarsieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7857-4771","authenticated-orcid":false,"given":"Alex","family":"Cagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Joanna","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Follows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-2033","authenticated-orcid":false,"given":"Daniel J.","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9032-4700","authenticated-orcid":false,"given":"Ultan","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-8111","authenticated-orcid":false,"given":"Gary J.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-4416","authenticated-orcid":false,"given":"Inigo","family":"Martincorena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1327-2334","authenticated-orcid":false,"given":"Krishnaa","family":"Mahbubani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0633-3696","authenticated-orcid":false,"given":"Kourosh","family":"Saeb Parsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-9659","authenticated-orcid":false,"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-2932","authenticated-orcid":false,"given":"Margaret A.","family":"Goodell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7871-8811","authenticated-orcid":false,"given":"David","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9917-9092","authenticated-orcid":false,"given":"Elisa","family":"Laurenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3921-0510","authenticated-orcid":false,"given":"Peter J.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1839-7785","authenticated-orcid":false,"given":"Raheleh","family":"Rahbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7122-4608","authenticated-orcid":false,"given":"Jyoti","family":"Nangalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-153X","authenticated-orcid":false,"given":"Michael R.","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2234_CR1","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr.","year":"2008","unstructured":"DeVita, V. T. Jr. & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643\u20138653 (2008).","journal-title":"Cancer Res."},{"key":"2234_CR2","doi-asserted-by":"publisher","first-page":"960317","DOI":"10.3389\/fonc.2022.960317","volume":"12","author":"CM Tilsed","year":"2022","unstructured":"Tilsed, C. M., Fisher, S. A., Nowak, A. K., Lake, R. A. & Lesterhuis, W. J. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front. Oncol. 12, 960317 (2022).","journal-title":"Front. Oncol."},{"key":"2234_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s004320050156","volume":"124","author":"C Kollmannsberger","year":"1998","unstructured":"Kollmannsberger, C., Hartmann, J. T., Kanz, L. & Bokemeyer, C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J. Cancer Res. Clin. Oncol. 124, 207\u2013214 (1998).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2234_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","volume":"40","author":"S Bhatia","year":"2013","unstructured":"Bhatia, S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin. Oncol. 40, 666\u2013675 (2013).","journal-title":"Semin. Oncol."},{"key":"2234_CR5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","volume":"5","author":"LM Morton","year":"2019","unstructured":"Morton, L. M. et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol. 5, 318\u2013325 (2019).","journal-title":"JAMA Oncol."},{"key":"2234_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/nrc722","volume":"2","author":"S Bhatia","year":"2002","unstructured":"Bhatia, S. & Sklar, C. Second cancers in survivors of childhood cancer. Nat. Rev. Cancer 2, 124\u2013132 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"2234_CR7","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1158\/1055-9965.EPI-06-0414","volume":"15","author":"LB Travis","year":"2006","unstructured":"Travis, L. B. The epidemiology of second primary cancers. Cancer Epidemiol. Biomarkers Prev. 15, 2020\u20132026 (2006).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"2234_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/nrc1749","volume":"5","author":"JM Allan","year":"2005","unstructured":"Allan, J. M. & Travis, L. B. Mechanisms of therapy-related carcinogenesis. Nat. Rev. Cancer 5, 943\u2013955 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"2234_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.ackd.2019.08.005","volume":"27","author":"A Nicolaysen","year":"2020","unstructured":"Nicolaysen, A. Nephrotoxic chemotherapy agents: old and new. Adv. Chronic Kidney Dis. 27, 38\u201349 (2020).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"2234_CR10","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman, J. E. & Itri, L. M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl Cancer Inst. 91, 1616\u20131634 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"2234_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford, J., Dale, D. C. & Lyman, G. H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100, 228\u2013237 (2004).","journal-title":"Cancer"},{"key":"2234_CR12","doi-asserted-by":"publisher","first-page":"1609742","DOI":"10.3389\/pore.2021.1609742","volume":"27","author":"R Sz\u00e1sz","year":"2021","unstructured":"Sz\u00e1sz, R., Telek, B. & Ill\u00e9s, \u00c1. Fludarabine\u2013cyclophosphamide\u2013rituximab treatment in chronic lymphocytic leukemia, focusing on long term cytopenias before and after the era of targeted therapies. Pathol. Oncol. Res. 27, 1609742 (2021).","journal-title":"Pathol. Oncol. Res."},{"key":"2234_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrc3634","volume":"14","author":"LL Robison","year":"2014","unstructured":"Robison, L. L. & Hudson, M. M. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat. Rev. Cancer 14, 61\u201370 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"2234_CR14","doi-asserted-by":"publisher","first-page":"101733","DOI":"10.1016\/j.canep.2020.101733","volume":"71","author":"F Erdmann","year":"2021","unstructured":"Erdmann, F. et al. Childhood cancer: survival, treatment modalities, late effects and improvements over time. Cancer Epidemiol. 71, 101733 (2021).","journal-title":"Cancer Epidemiol."},{"key":"2234_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"2234_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"2234_CR17","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","volume":"51","author":"O Pich","year":"2019","unstructured":"Pich, O. et al. The mutational footprints of cancer therapies. Nat. Genet. 51, 1732\u20131740 (2019).","journal-title":"Nat. Genet."},{"key":"2234_CR18","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.stem.2021.07.012","volume":"28","author":"JK de Kanter","year":"2021","unstructured":"de Kanter, J. K. et al. Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients. Cell Stem Cell 28, 1726\u20131739 (2021).","journal-title":"Cell Stem Cell"},{"key":"2234_CR19","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1672-7","volume":"574","author":"H Lee-Six","year":"2019","unstructured":"Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574, 532\u2013537 (2019).","journal-title":"Nature"},{"key":"2234_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-022-04712-2","volume":"605","author":"J Kaplanis","year":"2022","unstructured":"Kaplanis, J. et al. Genetic and chemotherapeutic influences on germline hypermutation. Nature 605, 503\u2013508 (2022).","journal-title":"Nature"},{"key":"2234_CR21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52, 1219\u20131226 (2020).","journal-title":"Nat. Genet."},{"key":"2234_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","volume":"23","author":"JI Hsu","year":"2018","unstructured":"Hsu, J. I. et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell 23, 700\u2013713 (2018).","journal-title":"Cell Stem Cell"},{"key":"2234_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"CC Coombs","year":"2017","unstructured":"Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374\u2013382 (2017).","journal-title":"Cell Stem Cell"},{"key":"2234_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","volume":"606","author":"E Mitchell","year":"2022","unstructured":"Mitchell, E. et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature 606, 343\u2013350 (2022).","journal-title":"Nature"},{"key":"2234_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-021-03477-4","volume":"593","author":"F Abascal","year":"2021","unstructured":"Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405\u2013410 (2021).","journal-title":"Nature"},{"key":"2234_CR26","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.tranon.2021.101169","volume":"14","author":"W Zhang","year":"2021","unstructured":"Zhang, W., Gou, P., Dupret, J.-M., Chomienne, C. & Rodrigues-Lima, F. Etoposide, an anticancer drug involved in therapy-related secondary leukemia: enzymes at play. Transl. Oncol. 14, 101169 (2021).","journal-title":"Transl. Oncol."},{"key":"2234_CR27","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2234_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","volume":"561","author":"H Lee-Six","year":"2018","unstructured":"Lee-Six, H. et al. Population dynamics of normal human blood inferred from somatic mutations. Nature 561, 473\u2013478 (2018).","journal-title":"Nature"},{"key":"2234_CR29","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.celrep.2018.11.014","volume":"25","author":"FG Osorio","year":"2018","unstructured":"Osorio, F. G. et al. Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis. Cell Rep. 25, 2308\u20132316 (2018).","journal-title":"Cell Rep."},{"key":"2234_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41586-022-05072-7","volume":"608","author":"HE Machado","year":"2022","unstructured":"Machado, H. E. et al. Diverse mutational landscapes in human lymphocytes. Nature 608, 724\u2013732 (2022).","journal-title":"Nature"},{"key":"2234_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","volume":"4","author":"F Maura","year":"2023","unstructured":"Maura, F. et al. Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and Reed Sternberg cells. Blood Cancer Discov. 4, 208\u2013227 (2023).","journal-title":"Blood Cancer Discov."},{"key":"2234_CR32","first-page":"1860","volume":"12","author":"EJM Bertrums","year":"2022","unstructured":"Bertrums, E. J. M. et al. Elevated mutational age in blood of children treated for cancer contributes to therapy-related myeloid neoplasms. Cancer Discov. 12, 1860\u20131872 (2022).","journal-title":"Cancer Discov."},{"key":"2234_CR33","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).","journal-title":"Nat. Commun."},{"key":"2234_CR34","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","volume":"11","author":"EH Rustad","year":"2020","unstructured":"Rustad, E. H. et al. Timing the initiation of multiple myeloma. Nat. Commun. 11, 1917 (2020).","journal-title":"Nat. Commun."},{"key":"2234_CR35","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","volume":"35","author":"F Maura","year":"2021","unstructured":"Maura, F. et al. The mutagenic impact of melphalan in multiple myeloma. Leukemia 35, 2145\u20132150 (2021).","journal-title":"Leukemia"},{"key":"2234_CR36","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1182\/blood.2020010150","volume":"137","author":"THH Coorens","year":"2021","unstructured":"Coorens, T. H. H. et al. Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. Blood 137, 2992\u20132997 (2021).","journal-title":"Blood"},{"key":"2234_CR37","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1038\/s41467-019-12594-8","volume":"10","author":"S Christensen","year":"2019","unstructured":"Christensen, S. et al. 5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. Nat. Commun. 10, 4571 (2019).","journal-title":"Nat. Commun."},{"key":"2234_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","volume":"606","author":"MA Fabre","year":"2022","unstructured":"Fabre, M. A. et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature 606, 335\u2013342 (2022).","journal-title":"Nature"},{"key":"2234_CR39","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.3324\/haematol.2023.282992","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach, P. et al. Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients. Haematologica 108, 3308\u20133320 (2023).","journal-title":"Haematologica"},{"key":"2234_CR40","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1100\/tsw.2002.863","volume":"2","author":"RA Brodsky","year":"2002","unstructured":"Brodsky, R. A. High dose cyclophosphamide treatment for autoimmune disorders. Sci. World J. 2, 1808\u20131815 (2002).","journal-title":"Sci. World J."},{"key":"2234_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41588-023-01602-9","volume":"56","author":"GCC Koh","year":"2024","unstructured":"Koh, G. C. C. et al. The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells. Nat. Genet. 56, 23\u201326 (2024).","journal-title":"Nat. Genet."},{"key":"2234_CR42","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","volume":"326","author":"RE Curtis","year":"1992","unstructured":"Curtis, R. E. et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N. Engl. J. Med. 326, 1745\u20131751 (1992).","journal-title":"N. Engl. J. Med."},{"key":"2234_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJM199001043220102","volume":"322","author":"JM Kaldor","year":"1990","unstructured":"Kaldor, J. M. et al. Leukemia following Hodgkin\u2019s disease. N. Engl. J. Med. 322, 7\u201313 (1990).","journal-title":"N. Engl. J. Med."},{"key":"2234_CR44","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","volume":"28","author":"C Mauz-K\u00f6rholz","year":"2010","unstructured":"Mauz-K\u00f6rholz, C. et al. Procarbazine-free OEPA\u2013COPDAC chemotherapy in boys and standard OPPA\u2013COPP in girls have comparable effectiveness in pediatric Hodgkin\u2019s lymphoma: the GPOH-HD-2002 study. J. Clin. Oncol. 28, 3680\u20133686 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2234_CR45","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst, B. et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 17, 928\u2013942 (2016).","journal-title":"Lancet Oncol."},{"key":"2234_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ejh.13429","volume":"105","author":"C Lacout","year":"2020","unstructured":"Lacout, C. et al. R\u2013DHA\u2013oxaliplatin (R-DHAOx) versus R\u2013DHA\u2013cisplatin (R-DHAP) regimen in B-cell lymphoma treatment: a eight-year trajectory study. Eur. J. Haematol. 105, 223\u2013230 (2020).","journal-title":"Eur. J. Haematol."},{"key":"2234_CR47","first-page":"256","volume":"8","author":"RK Mehmood","year":"2014","unstructured":"Mehmood, R. K. Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. Oncol. Rev. 8, 256 (2014).","journal-title":"Oncol. Rev."},{"key":"2234_CR48","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41596-020-00437-6","volume":"16","author":"P Ellis","year":"2021","unstructured":"Ellis, P. et al. Reliable detection of somatic mutations in solid tissues by laser-capture microdissection and low-input DNA sequencing. Nat. Protoc. 16, 841\u2013871 (2021).","journal-title":"Nat. Protoc."},{"key":"2234_CR49","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41586-020-2214-z","volume":"580","author":"L Moore","year":"2020","unstructured":"Moore, L. et al. The mutational landscape of normal human endometrial epithelium. Nature 580, 640\u2013646 (2020).","journal-title":"Nature"},{"key":"2234_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12862-018-1131-3","author":"DT Hoang","year":"2018","unstructured":"Hoang, D. T. et al. MPBoot: fast phylogenetic maximum parsimony tree inference and bootstrap approximation. BMC Evol. Biol. https:\/\/doi.org\/10.1186\/s12862-018-1131-3 (2018).","journal-title":"BMC Evol. Biol."},{"key":"2234_CR51","doi-asserted-by":"publisher","first-page":"lqad005","DOI":"10.1093\/nargab\/lqad005","volume":"5","author":"M Liu","year":"2023","unstructured":"Liu, M., Wu, Y., Jiang, N., Boot, A. & Rozen, S. G. mSigHdp: hierarchical Dirichlet process mixture modeling for mutational signature discovery. NAR Genom. Bioinform. 5, lqad005 (2023).","journal-title":"NAR Genom. Bioinform."},{"key":"2234_CR52","doi-asserted-by":"publisher","first-page":"btad756","DOI":"10.1093\/bioinformatics\/btad756","volume":"39","author":"M D\u00edaz-Gay","year":"2023","unstructured":"D\u00edaz-Gay, M. et al. Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment. Bioinformatics 39, btad756 (2023).","journal-title":"Bioinformatics"},{"key":"2234_CR53","doi-asserted-by":"publisher","unstructured":"Mitchell, E. Emily-mitchell\/chemotherapy: the long-term effects of chemotherapy on normal blood cells. Zenodo https:\/\/doi.org\/10.5281\/zenodo.15235476 (2025).","DOI":"10.5281\/zenodo.15235476"}],"updated-by":[{"DOI":"10.1038\/s41588-025-02315-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000}}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02234-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:42:03Z","timestamp":1757198523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02234-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1038\/s41588-025-02234-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.20.594942","asserted-by":"object"}]},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41588-025-02315-x","URL":"https:\/\/doi.org\/10.1038\/s41588-025-02315-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.J.D. and U.M. are employees of and shareholders in AstraZeneca. M.R.S. and P.J.C. are cofounders of and shareholders in Quotient Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}